Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA's Action Plan To Support ATMPs Expected In Jan 2017

Executive Summary

The European Medicines Agency's action plan to support the development of advanced therapy medicinal products will prioritize on actions that are feasible, will result in major gains without the need for a lot of effort and will not require legislative changes.

Advertisement

Related Content

EMA Identifies Steps To Foster ATMP Development
Gene Therapy Trials In EU Delayed By Environmental Considerations
EMA Guidance On Investigational ATMPs To Focus On Exploratory And Pivotal Trials
EMA Close To Finalizing Gene Therapy Products Guidance; No Scope For Further Approximation To International Norms
EMA’s PRIME Offers Hope To Advanced Therapies As More Get A “Yes”
Reform Vs. Improvements: No Decision Yet On Fate Of EU Advanced Therapies Law

Topics

Advertisement
UsernamePublicRestriction

Register

PS119743

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel